E.E. Geduld’s Lipocine LPCN Stock Holding History

E.E. Geduld’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$55K	Sell	882 -883	-50%	-$55.9K	0.03%	130
2016 Q3	$134K	Hold	1,765	–	–	0.13%	111
2016 Q2	$91K	Buy	+1,765	New	+$273K	0.12%	111
2015 Q3	–	Sell	-1,176	Closed	-$172K	–	244
2015 Q2	$172K	Buy	+1,176	New	+$146K	0.11%	187

Other funds holding LPCN

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

E.E. Geduld's LPCN Position: Q4 2016 in Review

E.E. Geduld reduced its Lipocine (LPCN) stake by 50% in Q4 2016, selling an estimated $55.9K and leaving 882 shares worth $55K. The position accounts for 0.03% of the portfolio, ranked #130.

E.E. Geduld first reported a position in LPCN in Q2 2015 and has held it in 4 quarters since. The position peaked at $172K in Q2 2015. 58 funds tracked by Wall St. Rank hold LPCN as of Q4 2016.

E.E. Geduld held 882 shares of Lipocine worth $55K as of Q4 2016.
E.E. Geduld sold 883 Lipocine shares in Q4 2016, an estimated $55.9K.
Lipocine made up 0.03% of E.E. Geduld's portfolio in Q4 2016, its #130 holding.
E.E. Geduld first reported a position in Lipocine in Q2 2015 and has held it in 4 quarters since.
E.E. Geduld's Lipocine position peaked at $172K in Q2 2015.
58 funds tracked by Wall St. Rank held Lipocine as of Q4 2016.

Based on E.E. Geduld's 13F filing for Q4 2016, filed 8 Feb 2017.